Concepedia

Steven E. Rowland

SE

3

Publications

264

Citations

3

H-Index

2007

Active since

Affiliations

Merck Canada Inc. (Canada)(Current)

Steven E. Rowland is an author at Merck Canada Inc. (Canada) specializing in drug discovery, drug development, and molecular pharmacology.

Top concepts

MedicinePharmacologyDrug DiscoveryPharmacotherapyDrug DevelopmentRadiation OncologyMolecular Pharmacology

Publications per year

2007–2008

3

Publications

3

MF63 [2-(6-Chloro-1 H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation

Daigen Xu, Steven E. Rowland, Patsy Clark et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 151 citations

MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7 H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis

Patsy Clark, Steven E. Rowland, Danielle Denis et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 98 citations

Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species

Steven E. Rowland, Patsy Clark, Robert J. Gordon et al. · European Journal of Pharmacology · 2007 · 15 citations

Molecular Pharmacology, Pharmacological Characterization, Heterocyclic +8

Rows per page

1–3 of 3